News | Magnetic Resonance Imaging (MRI) | May 21, 2018

New Studies Highlight MRI Use for Prostate Cancer Screening and Management

Trio of studies explores new ways to reclassify prostate cancer grade, ability for MRI to help avoid unnecessary biopsies

New Studies Highlight MRI Use for Prostate Cancer Screening and Management

May 21, 2018 — Three new studies presented at the 113th annual meeting of the American Urological Association (AUA) highlight the effectiveness of magnetic resonance imaging (MRI) in the diagnosis and management of prostate cancer. The studies concur that use of MRI in the diagnosis of prostate cancer is increasing, and brings added value to screening and surveillance.

The studies, which will be presented by Stacy Loeb, M.D., AUA spokesperson and assistant professor of urology and population health at New York University, include:

Prostate Health Index and Multiparametric Magnetic Resonance Imaging to Predict Prostate Cancer Grade Reclassification in Active Surveillance: When used together, multiparametric magnetic resonance imaging (mpMRI) and Prostate Health Index (PHI) may be useful for decreasing the burden of prostate biopsies in men on active surveillance (AS), according to Johns Hopkins researchers. While both mpMRI and PHI have shown independently to be valuable in predicting prostate cancer grade reclassification (Gleason score >6) in patients enrolled in AS, researchers at Johns Hopkins aimed to identify the value of combining them for the purpose of predicting grade reclassification at the next AS biopsy.

Researchers retrospectively identified 205 men enrolled in the institution's AS program who underwent mpMRI and PHI within six months of each other, followed by a systematic mpMRI transrectal ultrasound (TRUS) biopsy. They then evaluated PHI and PHI density across Prostate Imaging Reporting and Data System (PI-RADS) V2.0 scores. The researchers compared results between men with and without grade reclassification before calculating receiver operating characteristic curves to compare the diagnostic value of the PI-RADS score combined with PHI, PHID or prostate-specific antigen doubling time (PSAD) for grade reclassification.

Results showed:

  • Men with grade reclassification on biopsy had a higher median PHI (34.6 vs. 31.6, p=0.03) and PHID (0.79 vs. 0.56, p=0.03) compared to men without grade reclassification;
  • PSA and PSAD were not significantly different between men with grade reclassification and those without it; and
  • Combined use of PHI < 24.4 and PI-RADS < 3 could have avoided 24 percent of active surveillance biopsies at the cost of missing only 4 percent of grade reclassification.

Contemporary National Trends in Prostate MRI Among Patients Undergoing a Prostate Biopsy: Results from a Privately Insured Patient Population: A growing number of men are undergoing prostate biopsy with mpMRI as opposed to conventional TRUS biopsy. Using a large cohort (more than 1 million men, aged 40-80 years, diagnosed with an elevated PSA from 2010 to 2016) from a private insurer database, researchers examined the adoption of the mpMRI.

Results showed:

  • Of the men diagnosed with elevated PSA, 3.9 percent underwent a prostate biopsy;
  • Annual rates of MRI among those men receiving prostate biopsies increased significantly, from 5.2 per thousand in 2010 to 13.5 per thousand in 2016; and
  • Use of mpMRI increased across all age groups; however, the largest and only significant increase in use was in men aged 60 to 65 (4.4 in 2010 to 16.0 in 2016).

Negative MRI: Which Patients Could Safely Avoid Prostate Biopsy? Results from Multi-Institutional Study in 401 Patients (MP57-08): Multiparametric MRI (mpMRI) is an effective tool to rule out clinically significant (Gleason > 3+4) and high-grade (Gleason > 4+3) prostate cancers and results could identify patients most likely to benefit from biopsy, according to this multi-institutional study of 401 patients. Using data from prostate biopsy databases at two referral centers, researchers examined diagnostic accuracy of mpMRI in men with negative mpMRI (PI-RADS <3 or Likert score <3) prior to biopsy.

Results showed:

  • Of the 401 patients with negative mpMRI, 136 were diagnosed with prostate cancer;
  • Forty-six patients were diagnosed with clinically significant disease and 20 patients with high-grade disease;
  • Negative predictive values for identifying prostate cancer, clinically significant prostate cancer or high-grade prostate cancer were 66 percent (265/401), 89 percent (355/401) and 95 percent (381/401); and
  • PSA doubling time and history of previous negative biopsy were independent predictors of non-clinically significant disease.

"In recent years, we've seen a growing body of research that supports the use of mpMRI in prostate cancer management," said Loeb. "These studies confirm the value of using this modality when possible, both for initial diagnosis and subsequent follow up as part of active surveillance protocols. They also show the potential for combining mpMRI with markers, such as the prostate health index, to reduce the number of biopsies."

For more information: www.aua2018.org

 

Related Content

FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
MRI and Computer Modeling Reveals How Wrist Bones Move

Using fast MRI, UC Davis researchers scanned left and right wrists of men and women and used the data to build computer models of the movement of wrist bones. The data could help understand wrist injuries such as carpal tunnel syndrome. Image courtesy of Brent Foster and Abhijit Chaudhari, UC Davis.

News | Magnetic Resonance Imaging (MRI) | February 19, 2019
In a just-published Journal of Biomechanics article, the researchers proved a longtime assumption about individuals'...
Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Siemens Healthineers Demonstrates Artificial Intelligence, Healthcare Digitalization at HIMSS19
News | Artificial Intelligence | February 13, 2019
February 13, 2019 — At the 2019 Healthcare Information and Management Systems Society (HIMSS) global conference and e
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Oxford University Hospitals Employs Barco Synergi for Multi-disciplinary Cancer Conferences
News | Oncology Diagnostics | February 06, 2019
Oxford University Hospitals (OUH) is trialing clinical collaboration technology from Barco for its Multi-disciplinary...
Study Assesses Risk of MRI Exams for Patients With Tattoos
News | Magnetic Resonance Imaging (MRI) | February 01, 2019
A new European study concluded that magnetic resonance imaging (MRI) exams pose little risk for people with tattoos,...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...